Ascentage 1H 2026 slides: 29% revenue growth, 9 trials advance

Ascentage Pharma Group International reported a 29% year-over-year revenue growth, amounting to $44.5 million for the first half of 2026, with product sales contributing $41.6 million. Despite the revenue increase, the stock price fell by 2.66% to $17.55 following the update. The company has nine registrational trials and is preparing for early U.S. commercialization efforts.

Research and development expenses rose to $102.8 million, while selling and distribution expenses increased to $33.4 million. Management stated that the current cash position provides runway through 2027, enough to support key trials and potential new drug application filings targeted for the second half of 2027. Ascentage's lisaftoclax, a Bcl-2 selective inhibitor, has demonstrated lower infection rates and serious adverse events compared to competing drugs in clinical trials.